BridgeBio Oncology Therapeutics, Inc. (BBOT) News
Track canonical SquawkNews coverage tagged to BBOT, BridgeBio Oncology Therapeutics, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 10 indexed stories across 4 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
BridgeBio Oncology Thera maintained at Buy by Canaccord Genuity
Canaccord Genuity maintained a Buy rating on BBOT, according to TradingView News.
EQUITY | Sep 09, 2026, 06:30 PM UTC
L
Stifel cuts BridgeBio Oncology price target to $15 from $23
Benzinga/TradingView reports Stifel cut its BridgeBio Oncology price target to $15.00 per share from $23.00.
EQUITY | Sep 09, 2026, 03:09 PM UTC
L
Wedbush maintains BridgeBio Oncology price target at $25.00
Wedbush maintained its BridgeBio Oncology price target at $25.00 per share, according to Benzinga’s ratings action summary.
EQUITY | Sep 09, 2026, 12:30 PM UTC
M
BridgeBio reports BBO-8520 response data, cash runway into 2028
BridgeBio said BBO-8520 plus pembrolizumab showed a 75% ORR at 500 mg QD, 53% across doses, and monotherapy produced a 63% ORR. It also said cash runway was $344.1 million into 2028.
REGULATION | Sep 08, 2026, 08:25 PM UTC
L
BBOT announces new BBO-8520 data and combo strategy
BBOT says it has new BBO-8520 data, highlighting a focus on its BBO-8520 combination for 2L+ NSCLC and combo programs in KRAS-mutant cancers.
EQUITY | Sep 08, 2026, 08:07 PM UTC
L
BridgeBio oncology unit may offer up to $500 million securities
BridgeBio Oncology Therapeutics Inc (BBOT) filed with the SEC to potentially offer up to $500 million in securities, according to TradingView News.
REGULATION | Sep 01, 2026, 09:36 PM UTC
L
BridgeBio Oncology leadership to participate in investor healthcare conferences
BridgeBio Oncology Therapeutics, Inc. announced leadership team participation in upcoming investor healthcare conferences.
EQUITY | Sep 01, 2026, 08:07 PM UTC
L
BBOT Reports Inducement Grants
BBOT reports inducement grants under Nasdaq Listing Rule 5635(c)(4)
EQUITY | Aug 11, 2026, 08:40 PM UTC
L
BridgeBio Oncology Q2 EPS $(705.20) Misses $(0.57) Estimate
BridgeBio Oncology (NASDAQ: BBOT ) reported quarterly losses of $(705.20) per share which missed the analyst consensus estimate of $(0.57) by 123619.3 percent. This is a 24.49 percent decrease over losses of $(566.46) pe
EARNINGS | Aug 11, 2026, 08:39 PM UTC
L
BBOT - BBOT Reports Second Quarter 2026 Financial Results and Update on Corporate Progress
BBOT - BBOT Reports Second Quarter 2026 Financial Results and Update on Corporate Progress
EARNINGS | Aug 11, 2026, 08:08 PM UTC